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Abstract
Introduction The effective treatment of chronic lower limb
ischemia is one of the most challenging issues confronting
vascular surgeons. Current pharmacological therapies play
an auxiliary role and cannot prevent disease progression,
and new treatment methods are needed. pl-VEGF165, a
gene therapy drug, was approved in Russia for the treat-
ment of atherosclerotic peripheral arterial disease (PAD)
after clinical studies in 2011. The study drug is an original
gene construction in which pl-VEGF165 1.2 mg is the
active substance.
Objective This postmarketing surveillance study was
undertaken to evaluate the safety (identification of
uncommon side effects) and efficacy of gene therapy in
patients in routine clinical practice.
Methods In total, 210 patients with stage II–III chronic
limb ischemia (according to the Fontaine classification
modified by AV Pokrovsky) in 33 healthcare facilities in
Russia and the Ukraine were enrolled in the study. The
control group (n = 60) received conservative therapy
without prostaglandins and prostacyclins, and the treatment
group (n = 150) received treatment with pl-VEGF165 as
two intramuscular injections for a total dose of 2.4 mg.
Pain-free walking distance (PWD) (the primary efficacy
criterion for Fontaine stages II–III), blood flow linear
velocity (BFLV), and ankle-brachial index (ABI) were
monitored for 6 months. The safety of pl-VEGF165 gene
transfer in terms of the trial protocol was initially evaluated
6 months after the start of the study; adverse events (AEs)
and serious adverse events (SAEs) were recorded during
both routine visits and unscheduled requests for medical
care.
Results Overall, PWD increased by 177%, from
100.3 ± 6.9 to 277.1 ± 16.2 m (p = 0.0001), in the
treatment group, whereas the mean value was unchanged in
the control group (p = 0.218). Both BFLV and ABI values
increased by 24% (p = 0.0001) in the treatment group but
decreased in the control group. The greatest therapeutic
effect was observed for stage III disease: PWD increased
by 683% (p = 0.0001). No angiogenic therapy-related AEs
or side effects were recorded, and target limb salvage was
96 and 97% in the treatment and control groups, respec-
tively. The results obtained in this study are not signifi-
cantly different from those observed in the phase IIb/III
registration clinical study completed in 2011.
Conclusion pl-VEGF165 intramuscular gene transfer is an
effective treatment for moderate to severe claudication due
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Key Points
pl-VEGF165 in combination with standard
pharmacological therapy significantly improves
clinical signs of claudication in patients with chronic
lower limb ischemia in routine clinical practice.
The results of this postmarketing surveillance study
showed that the therapeutic effect was most
noticeable in patients with stage IIb and III disease.
No angiogenic therapy-related adverse events or side
effects were recorded.
1 Introduction
Cardiovascular diseases (CVDs) are the third highest
nosological group—preceded only by cancer and heredi-
tary diseases—for which the feasibility of using gene
therapy has been widely studied, with 200 registered
clinical trials to date [1]. Given the significant role of
ischemia in the pathogenesis of most diseases in this group,
the therapeutic correction of tissue perfusion via induction
of vasculogenesis is a gene therapy application of interest.
This is primarily achieved using gene therapy constructions
based on viral and/or plasmid vectors with transcription
factor and growth factor genes capable of inducing pro-
liferation, migration, and differentiation of cellular ele-
ments of the vessel wall, such as endothelial cells and
fibroblasts, thus forming new blood vessels of the
microvasculature.
Several forms of peripheral arterial disease (PAD),
particularly atherosclerosis, lead to stage II–III ischemia
(intermittent claudication and critical lower extremity
ischemia without necrotic ulceration of the foot) and are
the first nosological entities of the CVDs in which a gene
therapy approach has been successfully integrated into
clinical practice; resulting in the retention of patients for at
least 3 years [2, 3]. The feasibility of using plasmid vector-
based gene therapeutic constructions for these purposes is
still under debate. No large studies, such as TAMARIS,
TALISMAN-201 (Therapeutic Angiogenesis Leg Ischemia
Study for the Management of Arteriopathy and Non-
Healing Ulcer), and RAVE (Regional Angiogenesis with
Vascular Endothelial Growth Factor (VEGF) in peripheral
arterial disease), have detected a reliable clinical effect
compared with placebo. Therefore, this method may be
considered ineffective because of its low transfection and
failure to achieve a significant level of target gene
expression at the injection site [4–6]. For our study,
because no differences have been previously observed with
the treatment of critical ischemia with ulcerous–necrotic
changes and diabetes mellitus when compared with a
control group, we chose a small population of patients with
clearly determined indications [4].
The active substance of the study drug is a plasmid with
the VEGF gene. The safety, feasibility, and long-term
efficacy of pl-VEGF165 were evaluated in a phase IIb/III
multicenter randomized trial in 2011 that enrolled 100
patients with intermittent claudication due to chronic lower
limb ischemia (stage IIa to III according to the Fontaine
classification modified by AV Pokrovsky) for whom
reconstructive surgery or endovascular treatment were
unsuitable [2]. The indications for its use meet the inclu-
sion criteria of this study.
As results from registration studies sometimes differ
from those in clinical practice [7], we examined the safety
and efficacy of pl-VEGF165 (Neovasculgen) in 33
healthcare facilities in Russia and the Ukraine (Clini-
calTrials.gov: NCT02369809) and compared the results
with those from postmarketing surveillance and registra-
tion phase IIb/III clinical studies [2, 3].
2 Materials and Methods
2.1 Study Population
Patients with intermittent claudication and critical lower
limb ischemia of atherosclerotic genesis that correlated with
stage II–III (a pain-free walking distance [PWD] of\200 m
and resting pain) according to the Fontaine–Pokrovsky
classification (2004) were enrolled in the study (n = 210)
and randomized into either the control group (n = 60) or
the treatment group (n = 150). Depending on the anatomy
and pathological process involved, patients had
atherosclerotic lesions of the following types: (1) proxi-
mal—primarily occlusion of the iliac-femoral and popliteal
arteries; (2) multilevel—occlusions in the iliac-femoral,
popliteal, and tibial arteries; or (3) distal—occlusions or
hemodynamically significant stenosis in tibial arteries.
2.2 Description of pl-VEGF165
The study drug is an original gene construction containing
a supercoiled plasmid DNA (1.2 mg)-encoding pCMV-
vegf165 as the active substance. It is now marketed as
‘Neovasculgen’ [2]. As stated, the indications for use meet
our inclusion criteria. The drug was supplied to the study
centers as a sterile lyophilisate that was then dissolved in
2 ml of water immediately before administration as an
intramuscular injection. The drug was administered into
calf muscles at four to five injection sites in the lower and
middle third of the posterior part of the calf.
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2.3 Study Design and Time Checkpoints
This was an open, controlled, prospective, comparative,
multicentre study design. All patients received standard
conservative therapy for chronic limb ischemia without
cilostazol and prostaglandins and without surgical or
endovascular vessel reconstruction. Surgical and endovas-
cular vessel reconstruction was unsuitable for all of the
patients. The study duration was 6 months, with control
examination time points upon enrolment and at 14, 90, and
180 days (Fig. 1).
Every patient was informed about the study goals and
objectives and the potential benefits and risks of partici-
pating prior to signing the voluntary informed consent
form. The study protocol was approved by the local ethics
committee at every study site. Eligible patients were ran-
domly assigned to either treatment arm using a computer-
generated block randomized list (block size 5) for every
individual patient using consecutively numbered and
sealed envelopes. The sealed envelopes were prepared in
advance of the study by one of the researchers, and the
local trial coordinator who enrolled patients and assigned
them to groups was unable to access the block randomized
list. Characteristic of this study design, the participants,
surgeons, and local trial coordinator were not blinded to the
group assignment.
2.4 Safety Assessment
Adverse events (AEs) and serious adverse events (SAEs)
were recorded to enable evaluation of drug safety at
6 months. An electrocardiogram (ECG), blood hematology
and biochemistry, a coagulation panel, and urinalysis were
performed for all patients during screening to detect any
concomitant and underlying disorders.
2.5 Efficacy Assessment
Given that patients with ulcerous-necrotic changes in limb
tissues were excluded from the study, a PWD value was used
as the primary efficacy endpoint. This was measured using a
treadmill with an elevation angle of 0 and a speed of 1 km/
h; the walking distance was recorded from the start to pain in
the limb muscle (evidence grade B according to the TASC-II
[Trans-Atlantic Inter-Society Consensus Document on
Management of Peripheral Arterial Disease]). Disease was
staged according to the Fontaine classification modified by
AV Pokrovsky, which is widely applied by Russian and
Ukrainian vascular surgeons. According to this classification,
a PWD[200 m indicates stage IIa disease, and\200 m but
[50 m indicates stage IIb disease; furthermore,\50 m and/
or resting pain without any ischemic tissue changes is the
classification for trophic ulcers and/or necrosis.
Visit 4 
180 (±2) days 
33 health care 
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Visit 0/1 Visit 2 
14 (±2) days 
Visit 3 
90 (±2) days 
Screening MonitoringTreatment
Blood and urine laboratory 
tests; electrocardiography ; 
measurement of 
PWD, ABI, BFV
Blood and urine 
laboratory 
tests; measurement of 
PWD, ABI, BFV 
Blood and urine laboratory 
tests; electrocardiography; measurement of 
PWD, ABI, BFV 
Fig. 1 Design of the
postmarketing surveillance
study. ABI ankle-brachial index,
BFLV blood flow linear
velocity, PWD pain-free walk
distance
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Secondary efficacy endpoints were blood flow linear
velocity (BFLV) of the affected extremity and the ankle-
brachial index (ABI) (Table 1). Mortality and amputa-
tion rates at 6 months were also calculated in both
groups.
2.6 Comparison of Postmarketing Surveillance
and Results of the Registration Phase IIB/III
Clinical Studies
A comparative analysis was conducted between the treat-
ment groups in the postmarketing surveillance (n = 150)
and the registration phase IIb/III clinical studies (n = 75)
using the primary and secondary efficacy endpoint values
[2, 3]. Baseline mean values for both groups are provided
in Table 1.
2.7 Statistical Data Processing
Absolute values of the efficacy endpoints (PWD, ABI, and
BFLV) complied with a non-normal distribution. There-
fore, non-parametric methods (Mann–Whitney U test and




No AEs related to the use of pl-VEGF165 were recorded.
Neither tumor formation nor impaired vision or any other
pathology that could indirectly indicate angiogenic therapy
Table 1 Baseline characteristics of postmarketing study subjects
Parameter Control group
(standard therapy; n = 60)
Treatment group
(pl- VEGF165; n = 150)
Treatment group (registration
phase IIb/III study; n = 75)
Average age 68.9 ± 7.1 62.7 ± 9.4 67.8 ± 9.0
Sex distribution
M 44 (74.0) 128 (85.0) 60 (80.0)
F 16 (26.0) 22 (15.0) 15 (20.0)
Diabetes mellitus
Type 1 1 (1.6) 3 (2.0) No
Type 2 5 (8.3) 13 (8.6) 12 (16.0)
Smoking
Yes 32 (53.0) 112 (74.0) 32 (42.6)
No 28 (47.0) 38 (26.0) 43 (57.3)
Previous revascularization
Yes 42 (70.0) 98 (62.0) 41 (54.6)
No 18 (30.0) 52 (38.0) 33 (45.4)
CAD
Yes 28 (46.6) 64 (42.6) 28 (37.3)
No 32 (53.4) 86 (57.4) 47 (62.7)
Severity of chronic limb ischemia
IIa 7 (11.0) 11 (7.0) 9 (12.0)
IIb 34 (57.0) 79 (53.0) 57 (76.0)
III 19 (32.0) 60 (40.0) 9 (12.0)
Level of occlusion
Proximal 19 (32.0) 35 (23.0) 38 (50.0)
Distal 24 (40.0) 97 (65.0) 16 (22.0)
Multilevel disease 17 (28.0) 18 (12.0) 21 (28.0)
PWD, m 110.3 ± 3.0 100.3 ± 7.1 135 ± 12.2
ABI, U 0.51 ± 0.01 0.49 ± 0.01 0.51 ± 0.02
BFLV, cm/s 18.2 ± 0.6 23.9 ± 2 14.2 ± 1.6
Data are presented as n (%) or mean ± standard deviation unless otherwise indicated
ABI ankle brachial index, BLFV blood flow linear velocity, CAD coronary artery disease, PWD pain-free walking distance
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complications were detected at any follow-up time points
in this study. Six patients from the treatment group
(n = 150) and two patients from the control group
(n = 60) underwent amputations after progression of crit-
ical ischemia. Thus, the amputation-free survival was 96
and 97% in the treatment and control groups, respectively
(Table 2).
3.2 Efficacy Assessment
A comparative analysis of the baseline values for each
patient group detected no significant differences in sex
composition, age, or primary and secondary endpoint val-
ues (Table 1); therefore, the groups were comparable. Both
groups consisted primarily of patients with distal lower
limb artery disease and stage IIb disease (Table 1).
The PWD increased from 100.3 ± 6.9 to
191.3 ± 11.9 m (p = 0.007) in patients treated with pl-
VEGF165 during the first 3 months of the study, and the
mean value was 277.1 ± 16.2 m by the end of the study,
an increase of 176% (p = 0.0001). Functional state did not
significantly change in the control group. The most evident
increase in the rate of PWD was observed in patients with
stage III disease (critical ischemia): from 24.6 ± 14.6 to
188.5 ± 31.6 m (683%) over 6 months (p = 0.000). In
patients with stage IIb disease, the PWD value increased
from 104.45 ± 5.1 to 278.08 ± 19.9 m (167%;
p = 0.000), whereas patients with stage IIa disease had the
lowest rate of increase: 253.1 ± 23.4 to 466.2 ± 39.5 m
(84%; p = 0.007).
The smallest increase in PWD, from 110.7 ± 14.9 to
246 ± 30 m (122%; p = 0.000), was observed in patients
with multilevel lower limb PAD. The PWD incremental
value was 167.4 m (175%) and 183.5 m (185%) in patients
with proximal and distal occlusions, respectively. The
PWD values did not change significantly in the control
group patients with all types of disease.
If the PWD incremental value of[30% is conditionally
accepted as a clinically significant effect of pl-VEGF165,
the success rate was 75% with the highest relative rate
among patients with stage IIb disease (Fig. 2). More
patients with stage III disease experienced a PWD incre-
mental value of[100% within 6 months.
The average BFLV increase in the treatment group was
5.8 cm/s, from 23.9 ± 2 to 29.7 ± 1.7 cm/s (p = 0.0001),
which correlated with improved macrohemodynamics, and
the ABI value increased from 0.49 ± 0.01 to 0.61 ± 0.02
by the end of the study (p = 0.0001). Conversely, the
control group exhibited a moderate decrease in BFLV and
ABI values, 3 and 2%, respectively, by the end of the
study. The differences in ABI and BFLV values between
the groups were already statistically significant at the
3-month time point (Table 3).
3.3 Comparative Evaluation of the Results
of the Postmarketing and Registration Phase
IIb/III Clinical Studies
More patients had stage III disease in the postmarketing
study treatment group than in the registration study: 40 and
12%, respectively. Therefore, the average PWD value in
the postmarketing study group was significantly lower, by
35 m (p = 0.004). In addition, more patients (50%) in the
phase IIb/III clinical study had proximal disease, whereas
65% of patients in the postmarketing study had distal
occlusions. There were no other differences between these
groups.
Table 2 Serious adverse events in the treatment and control study
groups during 6-month period
pl-VEGF165 (n = 150) Control (n = 60)




ACVE acute cerebrovascular event, AMI acute myocardial infarction
Fig. 2 Proportion of the treatment group patients with a pain-free
walk distance increase extent depending on the initial disease stage:
red indicates an increase of[100%; blue indicates an increase of
50–100%; purple indicates an increase from 30 to 50%; green
indicates an increase \30%; yellow indicates no increase; brown
indicates negative dynamics
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The use of pl-VEGF165 resulted in a statistically sig-
nificant increase in PWD: from 100.3 ± 6.9 to
277.1 ± 16.2 m (177%) and from 135.3 ± 12.2 to
284.7 ± 29.8 m (110%) in the postmarketing and phase
IIb/III clinical studies, respectively. In-group differences
became statistically significant in both groups at the
3-month time point. As the PWD incremental value was
more pronounced in the postmarketing study treatment
group, its baseline difference became balanced at
6 months, i.e., at that time the average PWD value was
277.1 ± 16.2 m (p = 0.0001) and 284.7 ± 29.8 m
(p = 0.0001) in the postmarketing and phase IIb/III clini-
cal studies, respectively. A comparative and selective
evaluation of the therapeutic effect in both studies indi-
cated similar tendencies: patients with stage III disease had
the most noticeable incremental PWD rate, and this
increase was significantly higher in these patients in the
postmarketing treatment group (683%) than in the regis-
tration clinical study (236%).
Because there were no significant between-group dif-
ferences in average ABI values at the start of the study, a
more noticeable positive parameter shift was observed in
the postmarketing study group (24 vs. 9% in the phase IIb/
III clinical trial). There was a statistically significant
increase in ABI values, 24 and 59%, in both studies
(Table 4).
4 Discussion
The objective of this postmarketing surveillance study was
to evaluate the safety and efficacy of pl-VEGF165 in
clinical practice. The treatment results for 210 patients at
33 study sites confirmed that pl-VEGF165 was well toler-
ated and not accompanied by drug-related AEs for at least
6 months. The introduction of pl-VEGF165 in a combined
treatment resulted in a significantly improved functional
state for patients with stage II–III chronic limb ischemia,
which manifested as an increase in average PWD of 177%
at 6 months and correlated with positive changes in
instrumental diagnostic parameters.
Only the TAMARIS study included more subjects and
study sites (i.e., 525 patients with critical limb ischemia of
multiple etiologies treated with a plasmid containing a gene
encoding fibroblast growth factor [FGF]) [4]. TAMARIS
included patients with end-stage disease, so amputation
rate was determined to be a stringent efficacy endpoint;
however, results for this endpoint did not differ from those
in the control group. It could be assumed that gene therapy
is less efficient in end-stage disease accompanied with
ischemic defects and the threat of amputation; however, as
other studies have shown this strategy to be effective [8],
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appropriate is unknown at this point, and results may
depend on the agent and method of delivery.
Given the severity of critical limb ischemia and the low
probability of a therapeutic effect from angiogenic therapy
on disease prognosis, only patients with earlier chronic
limb ischemia (intermittent claudication) were included in
this study and many others. A double-blind 13-month study
recruited 289 subjects treated with an adenovirus-based
gene therapy drug with a hypoxia-inducible factor-1 (HIF-
1) gene; PWD was also the primary efficacy endpoint [9].
This study indicated that gene induction of angiogenesis
via a local increase in endogenic HIF-1 synthesis at the
intermittent claudication stage was followed by a signifi-
cant increase in PWD in the treatment versus placebo
groups, which correlated with the ABI values. Thus, ther-
apeutic angiogenesis at the mid-term stages of disease is
more likely to prevent the progression of ischemia; our
study confirms this.
Despite numerous studies of angiogenic therapy for
PAD, pl-VEGF165 continues to be the only gene therapy
employed for the treatment of chronic limb ischemia in
Russia and the Ukraine. However, a number of drug can-
didates are undergoing phase III clinical studies, one of
which is a hepatocyte growth factor (HGF) plasmid known
as AMG0001. Two placebo-controlled clinical trials
[10, 11] in 131 subjects indicated this gene therapeutic
construction provided a statistically significant reduction in
ulcerous defect area in patients with critical limb ischemia,
in correlation with increased transcutaneous oxygen
(tcpO2) and ABI values, versus placebo. When planning
the phase III study, the investigators selected ‘time to
major amputation after angiogenesis induction’ as the pri-
mary efficacy endpoint because the study included patients
with the most severe disease, in whom a successful treat-
ment outcome was not expected. This could also be due to
their consideration of the TAMARIS study experience, as
this efficacy endpoint is less stringent than amputation rate;
however, it is useful in the achievement of a significant
difference versus placebo. Thus, we assume this gene
therapy drug would be registered and introduced into the
multifaceted treatment of patients with critical limb
ischemia should a statistically significant increase in limb
salvage time be observed.
A plasmid developed by ViroMed that expresses two
HGF isoforms is another candidate in gene therapy drugs,
and a phase III clinical study has been approved by the US
FDA (http://www.businesswire.com/news/home/201508
31006330/en/FDA-Approves-Initiation-ViroMeds-VM202-
Phase-III). Clinical studies demonstrated this drug resulted
in a significantly increased number of healed skin ischemic
defects in patients with critical limb ischemia. Among the
phase II study subjects, 60% had diabetic foot, for which









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Postmarketing Surveillance Study of pl-VEGF165 in PAD
investigators decided to change the inclusion criteria for
the phase III clinical study in favor of patients with
ischemic diabetic foot syndrome [12]. The study is
designed as a multicentre placebo-controlled study due to
start in 2016. The drug will be administered as an intra-
muscular injection in the lower leg, and the primary effi-
cacy endpoint will be the extent of ulcer defect dynamics.
However, our study has demonstrated that the selection of
patients with advanced disease creates unfavorable condi-
tions for therapeutic angiogenesis, and great care is
required when determining the exact patient population
that could benefit from plasmid-based gene therapy.
Although the open-label use of study drugs is a limita-
tion, this study was randomized and involved multiple
centers ([30 in two countries), and patient enrollment
decisions were made independently by a team of vascular
surgeons and radiologists on the basis of angiographic
results, disease history, previous procedures, and con-
comitant pathology. Therefore, we suggest these data can
be generalized, particularly to patient populations with
intermittent claudication.
5 Conclusions
The use of pl-VEGF165 in combination with standard
pharmacological therapy significantly improves clinical
signs of claudication in patients with chronic lower limb
ischemia. The international postmarketing surveillance
study indicated that gene therapy is as efficient in routine
clinical practice as it was in the phase IIb/III registration
clinical trial in patients with moderate to severe claudica-
tion due to stage IIa–III atherosclerotic chronic lower limb
ischemia. Therapeutic effect was most noticeable in
patients with stage IIb and III disease. No angiogenic
therapy-related AEs or side effects were recorded. How-
ever, further studies enrolling more patients are needed to
completely evaluate the effects of pl-VEGF165 gene
transfer in patients with pain at rest due to peripheral
atherosclerosis or autoimmune disorders and patients
undergoing peripheral arterial revascularization.
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